All In Biotech

Drug Trial Radar · NCT01265498

The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)

The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial

Last checked: Nov 20, 2026Latest source record: Apr 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 283 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

283

Actual

Start

Mar 2011

Primary completion

Jan 2014

Study completion Sep 2014

Sponsor

Sponsor type
NIH
First posted
Dec 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in improvement in their liver disease as measured by changes in the nonalcoholic fatty liver disease (NAFLD) activity score (NAS).

Conditions

  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • Nonalcoholic Steatohepatitis (NASH)

Interventions

  • obeticholic acidDrug

    25 mg daily for 72 weeks

  • placeboDrug

    placebo capsule, 25 mg daily for 72 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hepatic Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)Time frame: baseline to 72 weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Diego

    San Diego, California

  • University of California, San Francisco

    San Francisco, California

  • Indiana University

    Indianapolis, Indiana

  • St. Louis University

    St Louis, Missouri

  • Duke University Medical Center

    Durham, North Carolina

  • Case Western Reserve University

    Cleveland, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Virginia Commonwealth University

    Richmond, Virginia

  • Virginia Mason Medical Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.